<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933777</url>
  </required_header>
  <id_info>
    <org_study_id>SORAVE</org_study_id>
    <nct_id>NCT00933777</nct_id>
  </id_info>
  <brief_title>SORAVE - Sorafenib and Everolimus in Solid Tumors</brief_title>
  <acronym>SORAVE</acronym>
  <official_title>SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients With Relapsed Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and
      everolimus treatment in patients with relapsed solid tumors (finished).

      Extension part:Treatment of non-small cell lung cancer (NSCLC) with KRAS mutation after ≥ 1st
      relapse (recruiting)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose finding part: Patients will be recruited to receive combination of defined sorafenib
      dose (2x400mg) with increasing dose of everolimus (2.5mg, 5mg, 7.5mg, 10mg). There will be a
      run-in phase of 14 days of everolimus followed by combination sorafenib+everolimus starting
      from day 15. The combination will be continued as long as it is tolerated by the patient and
      the patient benefits from the treatment according to RECIST criteria. The maximal tolerated
      dose will be establish in 3+3 design. Patients will be recruited sequentially at least 14
      days apart. The next dose level according to 3+3 design will be initiated if all patients on
      the previous dose level reach day 29.

      Extension part: Patients will be treated with a dose of 7,5 mg Everolimus for 14 days (run-in
      phase) and sorafenib 2x 400 mg until progression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define a feasible treatment schedule for the combination therapy with sorafenib and everolimus</measure>
    <time_frame>July 2009 - December 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the maximum tolerated dose (MTDs) of everolimus in combination with 2 x 400 mg sorafenib daily</measure>
    <time_frame>July 2009 - December 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To analyze pharmacokinetic (PK) profiles (AUC, Cmax) of sorafenib and everolimus during combination therapy</measure>
    <time_frame>July 2009 - December 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile of the combination therapy with sorafenib + everolimus</measure>
    <time_frame>July 2009 - December 2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate KRAS-mutation status with treatment response (extension phase)</measure>
    <time_frame>December 2011 - December 2012</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Therapy with everolimus and sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of sorafenib and everolimus</intervention_name>
    <description>Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg</description>
    <arm_group_label>Therapy with everolimus and sorafenib</arm_group_label>
    <other_name>Nexavar, RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with solid tumors relapsed after and/or refractory to standard therapy (dose
             finding part), KRAS mutated NSCLC patients after ≥ 1st relapse for the extension phase

          -  ≥ 18 years of age

          -  Performance status ECOG 0-2

          -  Life expectancy of at least 12 weeks

          -  Subjects with at least one measurable (CT or MRI) lesion

          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to screening:

               -  Hemoglobin ≥ 9.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1,500 /mm3

               -  Platelet count ≥ 100 000/µL

               -  Total bilirubin ≤ 1,5x upper limit of normal (ULN)

               -  ALT and AST ≤ 2,5x ULN (≤ 5x ULN for patients with liver involvement)

               -  Alkaline phosphatase &lt; 4x ULN

               -  Potassium within normal limits (WNL) or correctable with supplements

               -  Total calcium (corrected for serum albumin) WNL or correctable with supplements

               -  Magnesium WNL or correctable with supplements

               -  PT-INR/PTT &lt; 1.5 x ULN [Patients who are being therapeutically anticoagulated
                  with an agent such as coumadin or heparin will be allowed to participate provided
                  that no prior evidence of underlying abnormality in these parameters exists]

               -  Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl) ≥
                  50 ml/min calculated by either Cockcroft-Gault or by 24 hours urine collection

          -  More than 14 days since previous systemic therapy, radiotherapy and surgery

          -  Negative urine or serum HCG in women of childbearing potential

          -  Signed and dated informed consent before the start of specific protocol procedures

        Exclusion Criteria:

          -  Squamous cell carcinoma histology in non-small cell lung cancer

          -  History of cardiac disease: congestive heart failure &gt; NYHA class 2; active Coronary
             Arterial Disease (CAD), (MI more than 6 months prior to study entry is allowed);
             cardiac arrythmias requiring anti-arrythmic therapy (except, when controlled by beta
             blockers or digoxin) or uncontrolled hypertension; for Extension phase: Long
             QT-Syndrome

          -  Active skin, mucosa, ocular or GI disorders of grade &gt; 1

          -  Uncontrolled diabetes

          -  ≥ grade 3 hypercholesterolemia/hypertriglyceridemia or ≥ grade 2 hypercholesterolemia
             / hypertriglyceridemia with history of CAD (despite lipid lowering treatment if given)

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of everolimus and sorafenib (e.g. ulcerative
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small
             bowel resection)

          -  History of HIV infection or previously sero-positive for the virus

          -  History of Hepatitis B or/and C or previously sero-positive for the Hepatitis B or/and
             C virus

          -  Leptomeningeal or uncontrolled brain metastases, including patients who continue to
             require glucocorticoids or intrathecal chemotherapy for brain or leptomeningeal
             metastases (documented by lumbar puncture)

          -  Treatment with any other investigational drugs within the previous 14 days

          -  Patients with seizure disorder requiring anti-epileptics

          -  History of organ allograft

          -  Patients with evidence or history of bleeding diathesis

          -  Patients undergoing renal dialysis

          -  Previous treatment with mTOR inhibitors and/or known hypersensitivity to mTOR
             inhibitors

          -  Past or current history of cancer other than the entry diagnosis EXCEPT cervical
             carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis &amp;
             T1] or any cancer curatively treated &gt; 3 years prior to study entry

          -  Any person being in an institution on assignment of the respective authority

          -  Any medical, mental or psychological condition which in the opinion of the
             investigator would not permit the patient to complete the study or understand the
             patient information

          -  Women who are pregnant or breast feeding, or women who are able to conceive and
             unwilling to practice an effective method of birth control (safe hormonal methods
             or/and barrier contraception) during study and 2 months after the last study drug
             intake

        For Extension part:

          -  Patients with medication that prolongs QTc and cannot be withdrawn (if the QTc
             prolonging medication is withdrawn - there must be a time interval of at least 7 days
             before starting treatment with sorafenib, in case of amiodarone the time interval is
             at least 90 days)

          -  Testing for Hepatitis B is mandatory
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Wolf, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lung Cancer Group Cologne, Center for Integrated Oncology, Dep.I of Internal Medicine, University Hospital Cologne, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Integrated Oncology, Dep.I of Internal Medicine, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cio-koeln-bonn.de</url>
  </link>
  <reference>
    <citation>Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.</citation>
    <PMID>17215530</PMID>
  </reference>
  <reference>
    <citation>Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10;23(11):2544-55. Epub 2005 Mar 7.</citation>
    <PMID>15753462</PMID>
  </reference>
  <reference>
    <citation>O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008 Apr 1;26(10):1588-95. doi: 10.1200/JCO.2007.14.0988. Epub 2008 Mar 10.</citation>
    <PMID>18332470</PMID>
  </reference>
  <reference>
    <citation>Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004 Mar 1;22(5):909-18.</citation>
    <PMID>14990647</PMID>
  </reference>
  <reference>
    <citation>Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004 Jan 22;350(4):379-92. Review. Erratum in: N Engl J Med. 2009 Apr 30;360(18):1917.</citation>
    <PMID>14736930</PMID>
  </reference>
  <reference>
    <citation>Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2010 Dec 20;28(36):5350.</citation>
    <PMID>18332469</PMID>
  </reference>
  <reference>
    <citation>Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol. 2003 Jan;45(1):49-59. Review.</citation>
    <PMID>12499064</PMID>
  </reference>
  <reference>
    <citation>Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005 Feb 10;23(5):965-72. Epub 2004 Dec 21.</citation>
    <PMID>15613696</PMID>
  </reference>
  <reference>
    <citation>Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005 Oct;16(10):1688-94. Epub 2005 Jul 8.</citation>
    <PMID>16006586</PMID>
  </reference>
  <reference>
    <citation>Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102. Review.</citation>
    <PMID>17272980</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lung Cancer Group Cologne</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Juergen Wolf</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

